# Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

> **NCT00494871** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1280 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Warfarin
- **DRUG:** Rivaroxaban placebo
- **DRUG:** Warfarin placebo

## Key facts

- **NCT ID:** NCT00494871
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 1280 (ACTUAL)
- **Last updated:** 2015-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494871, "Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00494871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*